Balyasny Asset Management’s Fate Therapeutics FATE Stock Holding History

Balyasny Asset Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.2K	Buy	+13,413	New	+$24.8K	﹤0.01%	2916
2024 Q1	–	Sell	-39,836	Closed	-$149K	–	2765
2023 Q4	$149K	Sell	39,836 -106,316	-73%	-$251K	﹤0.01%	2349
2023 Q3	$310K	Sell	146,152 -85,643	-37%	-$284K	﹤0.01%	1903
2023 Q2	$1.1M	Buy	231,795 +62,939	+37%	+$347K	﹤0.01%	1584
2023 Q1	$962K	Buy	+168,856	New	+$1.02M	﹤0.01%	1750
2018 Q2	–	Sell	-13,828	Closed	-$135K	–	1875
2018 Q1	$135K	Sell	13,828 -28,081	-67%	-$269K	﹤0.01%	1804
2017 Q4	$256K	Buy	41,909 +30,311	+261%	+$135K	﹤0.01%	1806
2017 Q3	$46K	Buy	+11,598	New	+$39.4K	﹤0.01%	1821

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Balyasny Asset Management's FATE Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Fate Therapeutics (FATE) in Q2 2026: 13,413 shares worth $36.2K. The stake represents ﹤0.01% of the portfolio and ranks #2916 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in FATE as recently as Q4 2023.

Balyasny Asset Management first reported a position in FATE in Q3 2017 and has held it in 8 quarters since. The position peaked at $1.1M in Q2 2023. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Balyasny Asset Management held 13,413 shares of Fate Therapeutics worth $36.2K as of Q2 2026.
Fate Therapeutics was a new Balyasny Asset Management position in Q2 2026.
Fate Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2916 holding.
Balyasny Asset Management first reported a position in Fate Therapeutics in Q3 2017 and has held it in 8 quarters since.
Balyasny Asset Management's Fate Therapeutics position peaked at $1.1M in Q2 2023.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.